AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01665105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
Study NCT01282138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
Description: One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
Study NCT02110277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAI/ultrasound Diagnostic Group
Description: These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
Study NCT01282138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)
Description: One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
Study NCT02441257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control ventilation
Description: patients are randomly divided to receive control or spontaneous ventilation randomly.
Study NCT04515563 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching exercise
Description: Control Group
Study NCT02441257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spontaneous ventilation
Description: patients are randomly divided to receive control or spontaneous ventilation randomly.
Study NCT01437761 — intervention group
Intervention type: DEVICE
Intervention: 2008 Sorbent System
Description: 2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
Study NCT06001463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSMed Dressing
Description: Half of the irradiated area was covered with CSMed® and the other half was under routine treatment. An irradiated area of 11cm\*14cm with best fit or easy accessibility was chosen for CSMed® dressing application. The area without dressing was treated with routine skin care in each patient.
Study NCT00240032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate injection with oral cetirizine hydrochloride
Description: Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
Study NCT00240032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glatiramer acetate with placebo
Description: Copaxone® injection 20 mg, oral placebo
Study NCT02949167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyHealth
Description: The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
Study NCT03865680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Description: The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
Study NCT03865680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duraphat
Description: The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
Study NCT05164354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Aromatherapy: It will be applied to each child three times, three days in a row. Each application will be 20 minutes. The application time will be decided together with the patient. At the end of the three-day practice.
Study NCT04320303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: expanded NK cells
Description: Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.
Study NCT03260738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation program with Poppy robot
Description: Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks. Among those 3 hours, patients receive 30 minutes of physical exercises dedicated to mobility of the spine supervised by robot Poppy.
Study NCT03260738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual rehabilitation program
Description: Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks.
Study NCT01215539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg. Subjects with evidence of complete response, partial response or stable disease will continue to receive the combination of chemotherapy with panitumumab until disease progression, unacceptable toxicity or withdrawal of consent.
Study NCT05164354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music concert
Description: Music Concert: In this study, a music (lullaby, classical music) to be preferred by the patient or family Children are played for 20 minutes once a day. (morning or afternoon) for three days to help the child sleep. The volume of the music being played will be preserved. Aromatherapy: To be applied each child three times for three consecutive days. Each one The application will take 20 minutes. It will be time to implement The decision is made with the patient. Finally The patient's sleep quality will increase in three days of application. measured by actigraphy.
Study NCT04471922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium enteric-coated tablet
Description: Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
Study NCT01165736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05150122
Description: single intravenous administration of 100 microgram PF-05150122
Study NCT04471922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
Study NCT04471922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active controlled (rabeprazole)
Description: Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
Study NCT00486187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Study NCT00486187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin or sulfonylurea
Study NCT03710629 — intervention group
Intervention type: OTHER
Intervention: Patients with driver genes
Description: Patients with driver genes
Study NCT04075227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% loteprednol etabonate
Description: Use topical 0.2% loteprednol etabonate eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
Study NCT04075227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% dexamethasone
Description: Use topical 0.1% dexamethasone eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
Study NCT01355432 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: There is no intervention, this is an observational study.
Study NCT04653415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 300mg
Description: The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone.
Study NCT04653415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone 125 mg
Description: The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone.
Study NCT04653415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tablet
Description: The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
Study NCT00351039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.
Study NCT00351039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.
Study NCT00351039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.
Study NCT01448096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
Study NCT01448096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic intrathecal chemotherapy
Description: Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
Study NCT03954808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery Training
Description: Motor imagery training will be designed for the individual basis with standard protocols
Study NCT01359280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Counseling
Description: 5 Sessions of theory-based medication adherence counseling
Study NCT01359280 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health Counseling
Description: 5 sessions of health improvement counseling
Study NCT01359280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: Daily medication regimen tailored adherence reminders delivered by cell phone
Study NCT01359280 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text Messages
Description: Daily medication regimen tailored adherence reminders delivered by cell phone
Study NCT02929121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients \<50 kg)
Study NCT04653415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 10 mL Injection
Description: The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
Study NCT03891277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous succinate
Description: Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.~placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
Study NCT03891277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous succinate
Description: Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.~placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
Study NCT01165736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05150122
Description: single oral administration of 100 microgram PF-05150122
Study NCT01165736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05241328
Description: single intravenous infusion of 100 microgram PF-05241328
Study NCT01165736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05241328
Description: single oral administration 100 microgram PF-05241328
Study NCT02929121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily tablet for 6 weeks: matching tablets containing no active ingredients
Study NCT04875845 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fasting for elective surgery
Description: 6-hours and 8-hours fasting before elective surgery
Study NCT03473158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound
Description: using the 6.5mHz intra-cavitary probe (65EC10EA) of ultrasound machine DP-50 (Shenzhen Mindray Bio-Medical Electronics Co., Ltd., P.R.China) to determine the number, site, size and cardiac activity of the fetuses, and monitor the fetal reduction procedure
Study NCT02429505 — intervention group
Intervention type: DRUG
Intervention: Miltefosine
Description: miltefosine: target 2.5 mg/kg/day for 28 days
Study NCT02898584 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BP Track
Study NCT01403233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cogniVida 50mg/day
Description: 2 capsules 25 mg (total 50 mg) cogniVida™ once a day
Study NCT01403233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cogniVida100mg/day
Description: 4 capsules 25 mg (total 100 mg) cogniVida™ once a day
Study NCT01403233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rebaudioside-A 303.7mg/day
Description: 4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
Study NCT02985970 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
Study NCT03473158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical fetal reduction
Description: under transvaginal ultrasound guidance, fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
Study NCT03473158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemical fetal reduction
Description: under transvaginal ultrasound guidance, fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
Study NCT04515563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-frequency, moderate-intensity walking group
Description: once-a-week walking exercise at moderate intensity
Study NCT04515563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-frequency, moderate-intensity walking group
Description: thrice-a-week walking exercise at moderate intensity
Study NCT04515563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-frequency, vigorous-intensity walking group
Description: once-a-week walking exercise at vigorous intensity
Study NCT01128920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin and Needle Hygiene Intervention
Description: Intervention incorporates psychoeducation, correction of false beliefs, counseling to counteract barriers to hygienic practices, motivational enhancement, and behavioral skills training in hygiene practices
Study NCT01128920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention - assessment-only condition
Description: No intervention is assigned in this condition
Study NCT03954808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Traditional physiotherapy within a specific program
Study NCT04398147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration
Study NCT00465283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
Study NCT00465283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
Study NCT02449447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT based on behavioral activation and cognitive therapy techniques including homework
Study NCT02449447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual in primary care including antidepressants and counselling
Study NCT02892708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: partial or complete resection followed by radiotherapy
Study NCT04515563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-frequency, vigorous-intensity walking group
Description: thrice-a-week walking exercise at vigorous intensity
Study NCT01761786 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C19 genotyping
Description: CYP2C19 genotyping will be performed in the intervention group. In patients with \*1/\*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (\*2 or \*3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
Study NCT01274130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Diavex 1000mg on Day1 and 750mg on Day2
Study NCT01529190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Effect of Preoperative Pregabalin on Pain Intensity. 300mg of pregabalin before surgical incision
Study NCT01529190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01242943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-L19SIP Radioimmunotherapy (RIT)
Description: Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy.~Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167.
Study NCT03150680 — intervention group
Intervention type: GENETIC
Intervention: SNPs associated with CAD, SNPs associated with pharmacological response to clopidogrel and statins
Description: Genotyping will be carried out by Next-Generation Sequencing (NGS)
Study NCT01120171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response,or unacceptable toxicity.
Study NCT01120171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal-encapsulated doxorubicin
Description: Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.~Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response or unacceptable toxicity.
Study NCT00312975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: Given intravenously every 3 months
Study NCT00312975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: best supportive care
Description: As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
Study NCT04305899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 1
Description: Specified dose on specified days
Study NCT04305899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 2
Description: Specified dose on specified days
Study NCT04398147 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration
Study NCT02892708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy after a brain biopsy
Study NCT02801227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
Study NCT02801227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Description: PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).